Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Minority Interest (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Minority Interest for 7 consecutive years, with -$192000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Minority Interest fell 2.67% year-over-year to -$192000.0, compared with a TTM value of -$192000.0 through Dec 2025, down 2.67%, and an annual FY2025 reading of -$192000.0, down 2.67% over the prior year.
  • Minority Interest was -$192000.0 for Q4 2025 at aTYR PHARMA, down from -$191000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at -$170000.0 in Q1 2021 and bottomed at -$192000.0 in Q4 2025.
  • Average Minority Interest over 5 years is -$182100.0, with a median of -$184000.0 recorded in 2024.
  • The sharpest move saw Minority Interest decreased 6.13% in 2021, then increased 0.54% in 2024.
  • Year by year, Minority Interest stood at -$175000.0 in 2021, then fell by 2.86% to -$180000.0 in 2022, then fell by 4.44% to -$188000.0 in 2023, then increased by 0.53% to -$187000.0 in 2024, then decreased by 2.67% to -$192000.0 in 2025.
  • Business Quant data shows Minority Interest for ATYR at -$192000.0 in Q4 2025, -$191000.0 in Q3 2025, and -$189000.0 in Q2 2025.